

## HOW TO ORDER A TEST



Order the OncoNext™ Liquid test kit from Eurofins Biomnis Ireland



Schedule a patient blood draw. Fasting is not required prior to a OncoNext Liquid test.



Draw a blood sample (10 ml)



Fill in the request form information and enclose the informed consent signed by the patient



Contact Eurofins Biomnis Ireland to arrange the sample transport



The results report is provided to the physician within 15 days



**ONCO NEXT RISK**  
Next Generation Oncology Diagnostics

Detects germline mutations involved in genetic predisposition to cancer

**ONCO NEXT LIQUID**  
Next Generation Oncology Diagnostics

Analysis of circulating tumour DNA (ctDNA) for cancer detection and monitoring (liquid biopsy)

**ONCO NEXT TISSUE**  
Next Generation Oncology Diagnostics

Detects somatic mutations in tumor DNA (tDNA) from tissue samples (traditional biopsy)



Liquid biopsy for detection of somatic mutations in circulating cell-free tumor DNA (ctDNA) from a blood sample

### ONCONEXT™: ADVANCED MOLECULAR DIAGNOSTICS SOLUTIONS USING STATE OF THE ART TECHNOLOGIES



**Test performed in Italy**  
(Rome or Milan)



Fast TAT: **15 days**



**20 years experience** in molecular diagnostics



Personalized **genetic counseling** with genetic counselors experts in discussing genetic test results and familial risks.



Laboratories **ISO 17025** accredited with groundbreaking technologies



Test available **worldwide**



Over **200,000** genetic tests/year



**Dedicated R&D team**  
Numerous peer-reviewed papers published in renowned international journals

design by evermind.it



**Eurofins Biomnis Ireland,**

Three Rock Road, Sandyford Industrial Estate, Dublin 18, D18 A4C0, Ireland

Tel.: (+35) 31 295 8545

E-mail: sales@eurofins-biomnis.ie



## PERSONALIZING CANCER CARE



Biomnis

“Liquid biopsy” is a non-invasive, highly sensitive and cost effective method of isolating and detecting cfDNA fragments, including circulating tumor DNA (ctDNA), from the plasma of patients diagnosed with cancer or from individuals who may have cancer. By analyzing cell-free DNA isolated from a patient’s blood, we can identify clinically relevant genomic alterations in ctDNA and match these alterations to targeted therapies and clinical trials.

TUMOR BIOPSY	ONCO NEXT LIQUID
Invasive and expensive	Non -invasive and less expensive
Specific to localized tumor site	Less dependent on original tumor site since tumor from both primary and metastatic sites release DNA into the bloodstream
Assessment of tumor heterogeneity limited to section of biopsy analyzed	Can capture tumor heterogeneity
Difficult to biopsy some organs	Easy to collect sample of blood
Not viable if primary tumor has been resected or if the tumor cannot be easily visualized via imaging studies	Allows for serial evaluation in absence of detectable primary tumor or metastases
A limited amount of tissue may be obtained for immunohistochemical and genomic analysis	A few copies of mutant ctDNA are sufficient for analysis
Serial biopsies are difficult to tolerate	Patient can tolerate serial blood draws for evaluation; may lead to greater compliance
	New tool that can be applied for evaluation of response to therapy and for detection of residual disease
	May allow for evaluation of development of resistance
	May aid in early detection of cancer

ONCO NEXT LIQUID offers a potential alternative to surgical tumor biopsy and histological assessment, eliminating many of the difficulties and concerns associated with traditional tests, as well as a means of augmenting imaging studies and other diagnostic methods.



## MONITOR

Detection of somatic mutations on circulating tumour DNA (ctDNA) for cancer monitoring

OncoNext Liquid™ Monitor test is meant for patients who have been diagnosed with cancer

Benefits provided by ONCO NEXT LIQUID Monitor



OncoNext™ Liquid Monitor provides physicians actionable biomarker information to help guide treatment and find ongoing clinical trials for aggressive, metastatic, and refractory cancer patients.

ONCO NEXT LIQUID test looks at a panel of genes known to be somatically altered in cancer, to identify genetic alterations that may be treated with targeted therapies.

<b>Breast</b> The test looks at a panel of 10 genes known to be somatically altered in breast cancer	<b>Colon</b> The test looks at a panel of 14 genes known to be somatically altered in colorectal cancer	<b>Lung</b> The test looks at a panel of 11 genes known to be somatically altered in lung cancer
ONCO NEXT LIQUID Monitor 15 genes	ONCO NEXT LIQUID Monitor 23 genes	ONCO NEXT LIQUID Monitor 50 genes

Eurofins Group also offers oncogene panels tailored for specific indications. Contact Eurofins Biomnis Ireland to learn more.

A broad base of high-priority target genes are used in all OncoNext™ Liquid Monitor tests, regardless of which mutations were originally detected in the patient’s tumor. This allows detection of arising clones that may create resistance to current therapies or reveal options for additional targeted therapies.



## SCAN

Detection of somatic mutations on circulating tumour DNA (ctDNA) for early detection of cancer


OncoNext Liquid™ Scan is meant for preventive surveillance of high-risk populations

Benefits provided by ONCO NEXT LIQUID Scan



EXAMPLES OF HIGH RISK POPULATIONS INCLUDE, BUT ARE NOT LIMITED TO:

- Known genetic predisposition to a specific cancer (e.g. the individual carries a BRCA1 mutation);
- Significant family history of cancer;
- Personal history of smoking;
- Exposure to known carcinogens (e.g. radon);
- Prolonged radiation or UV light exposure;
- History of hormone use (fertility drugs, progestogen-containing hormone replacement therapy)



ONCO NEXT LIQUID Scan test is designed to screen a set of cancer driver genes for somatic mutations that could indicate early disease:

ONCO NEXT LIQUID Scan 15 genes	ONCO NEXT LIQUID Scan 23 genes	ONCO NEXT LIQUID Scan 50 genes
--------------------------------	--------------------------------	--------------------------------